{
      "ptx_code": "PTX119",
      "chem_name": "Flutamide",
      "casrn": "13311-84-7",
      "dtxsid": "DTXSID7032004",
      "smiles": "CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F",
      "inchikey": "MKXKFYHWDHIYRV-UHFFFAOYSA-N",
      "label": "PTX119 | Flutamide",
      "drugbank_id": "DB00499",
      "use_class": "Pharmaceutical",
      "tox_class": "Hepatotoxicity",
      "chem_name_user": "Flutamide",
      "mw_g_mol": "276.21",
      "solubility_h2o_mol_liter": "8.91e-05",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "8.04e-09",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "6.48",
      "source_kaw": "LSER eq 1 exp. Descriptors",
      "pka_acid": "12.29",
      "pka_base": "",
      "source_pka": "UFZ; Sirius T3",
      "log_kow_liter_liter": "3.35",
      "source_kow": "PhysPropNCCT (COMPTOX)",
      "log_dlipw_ph74_liter_liter": "3.57",
      "source_dlipw": "Escher et al. 2017",
      "freely_dissolved_fraction": "0.33",
      "density_kg_liter": "1.37",
      "source_density": "COMPTOX",
      "average_mass": "276.21",
      "boiling_point": "",
      "source_boiling_point": "",
      "melting_point": "111.5 \u00b0C",
      "source_melting_point": "LKT Labs (Chemical company)",
      "vapor_pressure": "",
      "source_vapor_pressure": "",
      "baseline_drerio": "48.50",
      "baseline_dmagna": "40.30",
      "baseline_celegans": "88.92",
      "baseline_xlaevis": "51.03",
      "baseline_dmelanogaster": "345.01",
      "baseline_cells": "3.04e-05",
      "baseline_cells_generic_micromole_liter_free_ec10": "9.88e-06",
      "moa_drugbank": "Flutamide is a nonsteroidal antiandrogen that blocks the action of both endogenous and exogenous testosterone by binding to the androgen receptor. In addition Flutamide is a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen.",
      "protein_binding": "94-96%",
      "moa_t3db": "",
      "aop": [
            {
                  "AOP_id": 19,
                  "AOP_name": "Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) "
            },
            {
                  "AOP_id": 34,
                  "AOP_name": "LXR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 58,
                  "AOP_name": "NR1I3 (CAR) suppression leading to hepatic steatosis "
            },
            {
                  "AOP_id": 61,
                  "AOP_name": "NFE2L2/FXR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 148,
                  "AOP_name": "EGFR Activation Leading to Decreased Lung Function "
            },
            {
                  "AOP_id": 187,
                  "AOP_name": "Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage "
            },
            {
                  "AOP_id": 200,
                  "AOP_name": "Estrogen receptor activation leading to breast cancer   "
            }
      ],
      "targets": [
            "5-hydroxytryptamine receptor 6",
            "Androgen receptor",
            "Aryl hydrocarbon receptor",
            "Cytochrome P450 1A2",
            "Cytochrome P450 2C19",
            "Nuclear receptor subfamily 1 group I member 2",
            "Thromboxane A2 receptor"
      ]
}